drugset
drugset / Trial / NCT01645189

Safety and Efficacy of Hunterase

NCT01645189 ↗

Phase 3 Completed 6 enrolled Green Cross Corporation
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine the safety and efficacy of once weekly dosing of idursulfase-beta 0.5mg/kg administered by intravenous(IV) infusion for Hunter syndrome patients \< 6 years old.

Timeline

Start
2012-07
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Hunterase Protein / enzyme biologic 0.5 mg/kg Intravenous

Indications

No indication recorded.